文献速递青光眼神经眼科

统一进展整合的开角型青光眼结构分类模型

A Unified, Progression-Integrated, Structural Model for Classification of Open-Angle Glaucoma and Individuals at Risk.
PubMed 文献 · Am J Ophthalmol · 2026-08-10

本文提出一个整合风险分层、现代结构与功能诊断及进展速率的开角型青光眼分类系统,将疾病连续体分为7期,并引入「(+)疾病」修饰符标识活动性进展,旨在使分类与当代诊断和纵向风险评估对齐。

要点

  • 新系统将开角型青光眼连续体分为0至6期,0至2期基于风险因素框架用于无青光眼性视神经病变的眼。
  • 3期定义为OCT在视野缺损前检出青光眼性视神经病变,4期为缺损限于1个半侧视野。
  • 引入「(+)疾病」修饰符表示临床显著的活动性进展,提示需加强监测或治疗。

核心结论

  • 提出一个整合结构成像、功能测试和进展风险的开角型青光眼综合分期框架。
  • 通过纳入OCT定义的开角型青光眼性视神经病变和活动性进展修饰符,使疾病分类与当代诊断和纵向风险评估对齐。

研究设计与样本

  • 综合里程碑式随机临床试验和效用分析研究的数据。
  • 识别当前分类系统在「临床前期」窗口和黄斑脆弱性方面的关键缺口,并据此开发新分期框架。

主要发现

  • 新系统将青光眼连续体分为7期(0至6期)。
  • 0期(健康)为无可识别青光眼风险因素的个体。
  • 1期(有风险)为单个次要风险因素且计算风险低(如OHTS 5年风险<5%)。
  • 2期(可疑青光眼)需至少1个主要风险因素或至少2个次要风险因素。
  • 3期(轻度青光眼)为OCT在视野缺损发生前检出青光眼性视神经病变。

关键数值与推荐

  • 1期示例:眼压高治疗研究(OHTS)5年风险<5%,而非任意眼压切点。
  • 4期(中度青光眼)为周边视野损害限于1个半侧视野。
  • 5期(重度青光眼)依据中心5°受累和/或广泛病变反映对生活质量的影响。
  • 6期(终末期青光眼)反映显著的青光眼相关视觉残疾。

临床怎么用

  • 临床可依据风险因素框架将无青光眼性视神经病变的眼分为0至2期。
  • 使用OCT检测青光眼性视神经病变以识别3期,早于视野缺损出现。
  • 用「(+)疾病」修饰符标识活动性进展,提示需加强监测或治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To propose a comprehensive, evidence-based classification system for open-angle glaucoma that integrates risk profiling, modern optic nerve functional and structural diagnostic testing and analytics, and disease progression rate. METHODS: We synthesized data from landmark randomized clinical trials and utility analysis studies. Critical gaps in current systems were identified, specifically regarding the "preperimetric" window and macular vulnerability. A new staging framework was developed to align disease definitions with biological severity, rates of progression, and therapeutic urgency. RESULTS: The proposed system stratifies the glaucoma continuum into the following 7 stages. Stages 0, 1, and 2 are assigned using a formalized risk-factor framework in eyes without glaucomatous optic neuropathy (GON). Stage 0 (healthy) denotes individuals with no identifiable risk factors for glaucoma. Stage 1 (at risk) corresponds to a single minor risk factor with otherwise low calculated risk (eg, Ocular Hypertension Treatment Study 5-year risk <5% rather than arbitrary intraocular pressure cutoffs), whereas stage 2 (glaucoma suspect) requires at least 1 major risk factor or at least 2 minor risk factors. Stage 3 (mild glaucoma) reflects the presence of GON detected by optical coherence tomography before visual field loss occurs. Stage 4 (moderate glaucoma) denotes the presence of peripheral visual field damage limited to 1 visual hemifield. Stage 5 (severe glaucoma) uses central 5° involvement and/or widespread disease to reflect the impact on quality of life. Stage 6 (end-stage glaucoma) reflects significant glaucoma-related visual disability. A novel "(+) disease" modifier, analogous to retinopathy of prematurity staging systems, is introduced to denote clinically significant active progression, signaling the need for more intensive surveillance or treatment. CONCLUSIONS: We propose a comprehensive staging framework for open-angle glaucoma that integrates structural imaging, functional testing, and progression risk into a unified classification system. By incorporating optical coherence tomography-defined GON and a modifier for active progression, this framework is intended to align disease classification with contemporary diagnostics and longitudinal risk assessments.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. DE Moraes CG, Liebmann JM. A Unified, Progression-Integrated, Structural Model for Classification of Open-Angle Glaucoma and Individuals at Risk. Am J Ophthalmol. 2026. PMID: 42575407. doi:10.1016/j.ajo.2026.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。